Guidelines for the management of vitiligo: The European Dermatology Forum consensus

British Journal of Dermatology

Volumn 168, Issue 1, 2013, Pages 5-19

  Taieb, A ^a   Alomar, A ^b   Bohm M ^c   Dell'Anna, M L ^d   De Pase, A ^e   Eleftheriadou, V ^f   Ezzedine, K ^a   Gauthier, Y ^a   Gawkrodger, D J ^g   Jouary, T ^a   Leone, G ^d   Moretti, S ^h   Nieuweboer Krobotova, L ⁱ   Olsson, M J ^j   Parsad, D ^k   Passeron, T ^l   Tanew, A ^m   Van Der Veen, W ⁱ   Van Geel, N ⁿ   Whitton, M ^f   Wolkerstorfer, A ⁱ   Picardo, Mauro ^d   more..

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^e ARIV   (Italy)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ Netherlands Institute for Pigment Disorders   (Netherlands)

^j UPPSALA UNIVERSITY   (Sweden)

^k PIGMER   (India)

^l UNIVERSITÉ CÔTE D'AZUR   (France)

^m UNIVERSITY OF VIENNA   (Austria)

ⁿ GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; ETANERCEPT; FLUOCINOLONE ACETONIDE; FLUTICASONE PROPIONATE; INFLIXIMAB; PIMECROLIMUS; TACALCITOL; TACROLIMUS;

ACNE; AGITATION; CLINICAL EFFECTIVENESS; CYTOPENIA; DEPIGMENTATION; DRUG EFFICACY; ERYTHEMA; EXCIMER LASER; HAIR LOSS; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INSOMNIA; KIDNEY DISEASE; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; NAUSEA; NONSEGMENTAL VITILIGO; PHOTOCHEMOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PUVA; REVIEW; SEGMENTAL VITILIGO; SIDE EFFECT; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN DISEASE; TELANGIECTASIA; ULTRAVIOLET B RADIATION; VITILIGO; WEIGHT GAIN;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ANTIOXIDANTS; CALCINEURIN; CHECKLIST; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTOTHERAPY; SKIN LIGHTENING PREPARATIONS; STEROIDS; TREATMENT OUTCOME; VITILIGO;

EID: 84872843346     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11197.x     Document Type: Review

References (125)

1. Taieb A, Picardo M,. Epidemiology, definitions and classification. In: Vitiligo (, Taieb A, Picardo M, eds). Berlin, Heidelberg: Springer, 2010; 13-24.
2. Zhang XJ, Liu JB, Gui GP, et al. Characteristics of genetic epidemiology and genetic models for vitiligo. J Am Acad Dermatol 2004; 51: 383-90.
3. Taïeb A, Picardo M,; VETF members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20: 27-35.
4. Picardo M, Taieb A, eds. Vitiligo. Berlin, Heidelberg: Springer, 2010.
5. Taieb A, Picardo M,. Clinical practice: vitiligo. N Engl J Med 2009; 360: 160-9.
6. Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev 2010; 1: CD003263.
7. Gawkrodger DJ, Ormerod AL, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008; 159: 1051-76.
8. Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol 1998; 134: 1532-40.
9. Westerhof W, Nieuweboer-Krobotova L, Mulder PGH, Glazenburg EJ,. Left-right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999; 135: 1061-6.
10. Kumari J,. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984; 120: 631-5.
11. Schaffer JV, Bolognia JL,. The treatment of hypopigmentation in children. Clin Dermatol 2003; 21: 296-310.
12. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.
13. Coskun B, Saral Y, Turgut D,. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88-91.
14. Köse O, Arca E, Kurumlu Z,. Mometasone cream versus pimecrolimus cream for the treatment of childhood vitiligo. J Dermatolog Treat 2010; 21: 133-9.
15. Grimes PE, Soriano T, Dytoc MT,. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91.
16. Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51: 52-61.
17. Lan CCE, Wu CS, Chen GS, Yu HS,. FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin. Br J Dermatol 2011; 164: 490-6.
18. Dawid M, Veensalu M, Grassberger M, Wolff K,. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006; 4: 942-6.
19. Kawalek AZ, Spencer JM, Phelps RG,. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30: 130-5.
20. Mehrabi D, Pandya AG,. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006; 142: 927-9.
21. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065-9.
22. Ostovari N, Passeron T, Lacour JP, Ortonne JP,. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 2006; 142: 252-3.
23. Kanwar AJ, Dogra S, Parsad D,. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol 2004; 29: 589-92.
24. Souza Leite RM, Craveiro Leite AA,. Two therapeutic challenges: periocular and genital vitiligo in children successfully treated with pimecrolimus cream. Int J Dermatol 2007; 46: 986-9.
25. Ho N, Pope E, Weinstein M, et al. A double-blind randomized placebo-controlled trial of topical tacrolimus 0.1% versus clobetasol propionate 0.05% in childhood vitiligo. Br J Dermatol 2011; 165: 626-32.
26. Stinco G, Piccirillo F, Forcione M, et al. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. Eur J Dermatol 2009; 19: 588-93.
27. Lotti T, Buggiani G, Troiano M, et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther 2008; 21: S20-6.
28. Hartmann A, Brocker EB, Hamm H,. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion. J Dtsch Dermatol Ges 2008; 6: 383-5.
29. Udompataikul M, Boonsupthip P, Siriwattanagate R,. Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo. J Dermatol 2011; 38: 536-40.
30. De D, Kanwar AJ,. Tacrolimus-induced hyperpigmentation in a patch of vitiligo. Skinmed 2008; 7: 93-4.
31. Pathak MA, Fitzpatrick TB,. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992. J Photochem Photobiol, B 1992; 14: 3-22.
32. Carrascosa JM, Gardeazabal J, Perez-Ferriols A, et al. Consensus document on phototherapy: PUVA therapy and narrow-band UVB therapy. Actas Dermosifiliogr 2005; 96: 635-58.
33. Wu CS, Lan CC, Wang LF, et al. Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo. Br J Dermatol 2007; 156: 122-9.
34. Bhatnagar A, Kanwar AJ, Parsad D,. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol 2007; 21: 638-42.
35. Dawe RS, Cameron H, Yule S, et al. A randomized controlled trial of narrowband ultraviolet B vs. bath-psoralen plus ultraviolet A photochemotherapy for psoriasis. Br J Dermatol 2003; 148: 1194-204.
36. Asawanonda P, Kijluakiat J, Korkij W, Sindhupak W,. Targeted broadband ultraviolet B phototherapy produces similar responses to targeted narrowband ultraviolet B phototherapy for vitiligo: a randomized, double-blind study. Acta Derm Venereol 2008; 88: 376-81.
37. Pathak MA, Mosher DB, Fitzpatrick TB,. Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5,8-trimethylpsoralen, and psoralen in vitiligo. Natl Cancer Inst Monogr 1984; 66: 165-73.
38. Yones SS, Palmer RA, Garibaldinos TM, Hawk JL,. Randomized double-blind trial of treatment of vitiligo: efficacy psoralen UVA therapy versus narrowband UVB therapy. Arch Dermatol 2007; 143: 578-84.
39. Morrison WL, Marwaha S, Beck L, et al. PUVA-induced phototoxicity: incidence and causes. J Am Acad Dermatol 1997; 36: 183-6.
40. Ortel B, Tanew A, Honigsmann H,. Treatment of vitiligo with khellin and ultraviolet A. J Am Acad Dermatol 1988; 18: 693-701.
41. Orecchia G, Perfetti L,. Photochemotherapy with topical khellin and sunlight in vitiligo. Dermatology 1992; 184: 120-3.
42. Anbar TS, Westerhof W, Abdel-Rahman AT, El-Khayyat MA,. Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. Photodermatol Photoimmunol Photomed 2006; 22: 157-63.
43. Diffey BL, Farr PM,. The challenge of follow-up in narrowband ultraviolet B phototherapy. Br J Dermatol 2007; 157: 344-9.
44. Njoo MD, Bos JD, Westerhof W,. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 42: 245-55.
45. Westerhof W, Nieuweboer-Krobotova L,. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol 1997; 133: 1525-8.
46. Parsad D, Kanwar AJ, Kumar B,. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 175-7.
47. Baltas E, Csoma Z, Ignacz F, et al. Treatment of vitiligo with the 308 nm xenon chloride excimer laser. Arch Dermatol 2002; 138: 1619-20.
48. Bianchi B, Campolmi P, Mavilla L, et al. Monochromatic excimer light (308 nm): an immunohistochemical study of cutaneous T cells and apoptosis related molecules in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 408-13.
49. Casacci M, Thomas P, Pacifico A, et al. Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311-313 nm) in the treatment of vitiligo-a multicentre controlled study. J Eur Acad Dermatol Venereol 2007; 21: 956-63.
50. Leone G, Iacovelli P, Paro Vidolin A, Picardo M,. Monochromatic excimer light 308 nm in the treatment of vitiligo: a pilot study. J Eur Acad Dermatol Venereol 2003; 17: 531-7.
51. Pacifico A, Leone G,. Photo(chemo)therapy in vitiligo. Photodermatol Photoimmunol Photomed 2011; 27: 261-77.
52. Sassi F, Cazzaniga S, Tessari G, et al. Randomized controlled trial comparing the effectiveness of 308 nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. Br J Dermatol 2008; 159: 1186-91.
53. Castanedo-Cazares JP, Lepe V, Moncada B,. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet B narrow band. Photodermatol Photoimmunol Photomed 2003; 19: 35-6.
54. Fai D, Cassano N, Vena GA,. Narrowband UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol 2007; 21: 916-20.
55. Nordal E, Guleng G, Rönnevig J,. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study. J Eur Acad Dermatol Venereol 2011; 25: 1440-3.
56. Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S,. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat 2009; 20: 14-18.
57. Baysal V, Yildrim M, Erel A, Kesig D,. Is the combination of calcipotriol and PUVA effective in vitiligo? J Eur Acad Dermatol Venereol 2003; 17: 299-302.
58. Leone G, Pacifico A, Iocovelli P, Paro Vidolin A,. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol 2006; 31: 200-5.
59. Tang LY, Fu WW, Xiang LH, et al. Topical tacalcitol and 308 nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. Photodermatol Photoimmunol Photomed 2006; 22: 310-14.
60. Goldinger SM, Dummer R, Schmid P, et al. Combination of 308 nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol 2007; 21: 504-8.
61. Oh SH, Kim T, Jee H, et al. Combination treatment of non-segmental vitiligo with a 308-nm xenon chloride excimer laser and topical high-concentration tacalcitol: a prospective, single-blinded, paired, comparative study. J Am Acad Dermatol 2011; 65: 428-30.
62. Parsad D, Saini R, Nagpal R,. Calcipotriol in vitiligo: a preliminary study. Pediatr Dermatol 1999; 16: 317-20.
63. Schallreuter KU, Wood JM, Lemke KR, Levenig C,. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study of 33 patients. Dermatology 1995; 190: 223-9.
64. Bakis-Petsoglou S, Le Guay JL, Wittal R,. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 2009; 161: 910-17.
65. Dell'Anna ML, Mastrofrancesco A, Sala R, et al. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol 2007; 32: 631-6.
66. Middelkamp-Hup MA, Bos JD, Riuz-Diaz F, et al. Treatment of vitiligo vulgaris with narrow band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo controlled study. J Eur Acad Dermatol Venereol 2007; 21: 942-50.
67. Hann SK, Im S, Park YK, Hur W,. Repigmentation of leukotrichia by epidermal grafting and systemic psoralen plus UVA. Arch Dermatol 1992; 128: 998-9.
68. Tsukamoto K, Osada A, Kitamura R, et al. Approaches to repigmentation of vitiligo skin: new treatment with ultrasonic abrasion, seed-grafting and psoralen plus ultraviolet A therapy. Pigment Cell Res 2002; 15: 331-4.
69. Anbar TS, Westerhof W, Abdel-Rahman T, et al. Effect of one session of ER:YAG laser ablation plus topical 5Fluorouracil on the outcome of short-term NB-UVB phototherapy in the treatment of non-segmental vitiligo: a left-right comparative study. Photodermatol Photoimmunol Photomed 2008; 24: 322-9.
70. Van Geel N, Ongenae K, De Mil M, et al. Double-blind placebo controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Arch Dermatol 2004; 140: 1203-8.
71. Bayoumi W, Fontas E, Silard L, et al. Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations. Br J Dermatol 2012; 166: 208-11.
72. Shin J, Lee JS, Hann SK, Oh SH,. Combination treatment by 10 600 nm ablative fractional carbon dioxide laser and narrowband ultraviolet B in refractory nonsegmental vitiligo: a prospective, randomized half-body comparative study. Br J Dermatol 2012; 166: 658-61.
73. Barman KD, Khaitan BK, Verma KK,. A comparative study of punch grafting followed by topical corticosteroid versus punch grafting followed by PUVA therapy in stable vitiligo. Dermatol Surg 2004; 30: 49-53.
74. Radmanesh M, Saedi K,. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 2006; 17: 151-3.
75. Pasricha JS, Seetharam KA, Dashore A,. Evaluation of five different regimes for the treatment of vitiligo. Indian J Dermatol Venereol Leprol 1989; 55: 18-21.
76. Pasricha JS, Khaitan BK,. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 1993; 32: 753-7.
77. Radakovic-Fijan S, Furnsinn-Fridl AM, Honigsmann H, Tanew A,. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 2001; 44: 814-17.
78. Kim SM, Lee HS, Hann SK,. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999; 38: 546-50.
79. Rath N, Kar HK, Sabhnani S,. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol 2008; 74: 357-60.
80. Gokhale BB,. Cyclophosphamide and vitiligo. Int J Dermatol 1979; 18: 92.
81. Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 126: 339-50.
82. Rigopoulos D, Gregorious S, Larios G, et al. Etanercept in the treatment of vitiligo. Dermatology 2007; 215: 84-5.
83. Smith DI, Heffernan MP,. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol 2008; 58: S50-1.
84. Ramírez-Hernández M, Marras C, Martínez-Escribano JA,. Infliximab-induced vitiligo. Dermatology 2005; 210: 79-80.
85. Dell'Anna ML, Picardo M,. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006; 19: 406-11.
86. Picardo M, Dell'Anna ML,. Vitamins and antioxidants: topical and systemic. In: Vitiligo (, Picardo M, Taieb A, eds). Berlin: Springer, 2010; 369-74.
87. Akyol M, Celik VK, Ozcelik S, et al. The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA. Eur J Dermatol 2002; 12: 24-6.
88. Parsad D, Pandhi R, Juneja A,. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 2002; 28: 285-7.
89. Schallreuter KU, Kruger C, Wurfel BA, et al. From basic research to bedside: efficacy of topical treatment with pseudo catalase PC-KUS in 71 children with vitiligo. Int J Dermatol 2008; 188: 215-18.
90. Sanclemente G, Garcia JJ, Zuleta JJ, et al. A double-blind, randomized trial of 0.05% betamethasone vs topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol 2008; 22: 1359-64.
91. Hercberg S, Ezzedine K, Guinot C, et al. Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr 2007; 137: 2098-105.
92. Njoo MD, Bos JD, Westerhof W, Bossuyt PM,. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol 1998; 134: 1543-9.
93. Gauthier Y,. Complications and limitations of melanocyte transplantation. In: Surgical Management of Vitiligo (, Gupta S, Olsson M, Kanwar AJ, Ortonne JP, eds). Oxford: Blackwell Publishing, 2007; 144-7.
94. Olsson MJ, Juhlin L,. Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. Br J Dermatol 2002; 147: 893-904.
95. Falabella R,. Surgical treatment of vitiligo. Why, when and how? J Eur Acad Dermatol Venereol 2003; 17: 518-20.
96. Olsson MJ,. What are the needs for transplantation treatment in vitiligo, and how good is it? Arch Dermatol 2004; 104: 1273-4.
97. Gupta S, Narang T, Olsson MJ, Ortonne JP,. Surgical management of vitiligo and other leukodermas: evidence-based practice guidelines. In: Surgical Management of Vitiligo (, Gupta S, Olsson M, Kanwar AJ, Ortonne JP, eds). Oxford: Blackwell Publishing, 2007; 69-79.
98. Parsad D, Gupta S,. Standard guidelines of care for vitiligo surgery. Indian J Dermatol Venereol Leprol 2008; 74: 37-45.
99. Lee DY, Choi SC,. A proposal for the treatment guideline in segmental vitiligo. Int J Dermatol 2012; doi:10.1111/j.1365-4632.2010.04694.x [Epub ahead of print].
100. Tanioka M, Yamamoto Y, Kato M, Miyachi Y,. Camouflage for patients with vitiligo vulgaris improved their quality of life. J Cosmet Dermatol 2010; 9: 72-5.
101. DePase A,. 'La Voce dei Pazienti'. Evidence Based Dermatology. Milan: Masson Publisher, 2003.
102. Ongenae K, Dierckxsens L, Brochez L, et al. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005; 210: 279-85.
103. Savin J,. The hidden face of dermatology. Clin Exp Dermatol 1993; 18: 393-5.
104. De Cuyper C,. Permanent makeup: indications and complications. Clin Dermatol 2008; 26: 30-4.
105. Njoo MD, Vodegel RM, Westerhof W,. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol 2000; 42: 760-9.
106. Rao J, Fitzpatrick RE,. Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg 2004; 30: 1043-5.
107. Kasraee B, Fallahi MR, Ardekani GS, et al. Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin. Exp Dermatol 2006; 15: 509-14.
108. Kim YJ, Chung BS, Choi KC,. Depigmentation therapy with Q-switched ruby laser after tanning in vitiligo universalis. Dermatol Surg 2001; 27: 969-70.
109. Nordlund JJ,. Depigmentation for the treatment of extensive vitiligo. In: Vitiligo (, Hann SK, Nordlund JJ, eds). Oxford: Blackwell Science, 2000; 207-13.
110. Solano F, Briganti S, Picardo M, Ghanem G,. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res 2006; 19: 550-71.
111. Alghamdi K, Kumar A,. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venerol 2011; 25: 749-57.
112. Radmanesh M,. Depigmentation of the normally pigmented patches in universal vitiligo patients with cryotherapy. J Eur Acad Dermatol Venereol 2000; 14: 149-52.
113. Di Nuzzo S, Masotti A,. Depigmentation therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole. Clin Exp Dermatol 2010; 35: 215-16.
114. Linthorst Homan MW, Spuls PI, De Korte J, et al. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 2009; 61: 411-20.
115. Thompson AR, Clarke SA, Newell RJ, Gawkrodger,; Appearance Research Collaboration. Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo. Br J Dermatol 2010; 163: 481-6.
116. Kostoupolou P, Taieb A,. Psychological interventions. In: Vitiligo (, Picardo M, Taieb A, eds). Berlin: Springer, 2009; 433-5.
117. Kostopolou P, Juoary T, Quintard B, et al. Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral centre. Br J Dermatol 2009; 161: 128-33.
118. Talsania N, Lamb B, Bewley A,. Vitiligo is more than skin deep: a survey of members of the Vitiligo Society. Clin Exp Dermatol 2009; 35: 736-9.
119. Taieb A,. Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell Res 2000; 13: 41-7.
120. Harms J, Lautenschlager S, Minder CE, Minder EI,. An alpha-melanocyte- stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009; 360: 306-7.
121. Bondanza S, Maurelli R, Paterna P, et al. Keratinocyte cultures from involved skin in vitiligo patients show an impaired in vitro behaviour. Pigment Cell Res 2007; 20: 288-300.
122. Rezvani HR, Cario-Andrè M, Pain C, et al. Protection of normal human reconstructed epidermis from UV by catalase overexpression. Cancer Gene Ther 2006; 14: 174-86.
123. Kapoor R, Phiske MM, Jerajani HR,. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol 2009; 160: 861-3.
124. Lan CC, Wu CS, Chiou MH, et al. Low-energy helium-neon laser induces locomotion of the immature melanoblasts and promotes melanogenesis of the more differentiated melanoblasts: recapitulation of vitiligo repigmentation in vitro. J Invest Dermatol 2006; 126: 2119-26.
125. Takahashi K, Tanabe K, Ohnuki M,. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-72.